血清t-PSA及f-PSA和CgA对前列腺癌的诊断价值与术后观察  被引量:2

Diagnostic value and postoperative observation of serum t-PSA,f-PSA,and CgA for patients with prostate cancer

在线阅读下载全文

作  者:徐志明 邓卫武 史争虎 廖思钦 邹文毕 Xu Zhiming;Deng Weiwu;Shi Zhenghu;Liao Siqin;Zou Wenbi(Sanshui District People’s Hospital,Foshan 528100,China;Department of Clinical Lab,Second Hospital,Shanxi University of Chinese Medicine,Xianyang 712000,China)

机构地区:[1]佛山市三水区人民医院,528100 [2]陕西中医药大学第二附属医院检验科,咸阳712000

出  处:《国际医药卫生导报》2020年第14期2101-2103,共3页International Medicine and Health Guidance News

摘  要:目的探讨总前列腺特异性抗原(t-PSA),游离列腺特异性抗原(f-PSA)和嗜铬粒蛋白A(CgA)在前列腺癌的诊断价值和术后观察。方法检测前列腺癌组(n=50)、前列腺良性疾病组(n=52)和健康对照组(n=55)血清t-PSA、f-PSA和CgA水平,并采用受试者工作特征曲线(ROC)比较单一及其联合指标。结果前列腺癌患者血清中t-PSA、f-PSA和CgA的水平均显著高于良性病变组和健康对照组,差异均有统计学意义(均P<0.05);良性病变组与健康对照组比较,差异均无统计学意义(均P>0.05);联合3个指标对前列腺癌和非前列腺癌诊断准确率为92.9%,灵敏度和特异性分别为94.3%、92.1%;前列腺癌患者在术后血清中f-PSA、t-PSA和CgA浓度迅速降低。结论联合检测血清标志物t-PSA、f-PSA和CgA是最优的组合模式,有助于前列腺癌的诊断和术后观察。Objective To evaluate the diagnostic value of serum tumor t-PSA,f-PSA,and chromogranin A for patients with prostate cancer,and to obtain an optimal pattern of combined tumor markers.Methods The serum levels of t-PSA,f-PSA,and chromogranin A in 50 patients with prostate cancer,52 patients with benign prostate diseases,and 55 normal controls were measured;and data were analyzed by the receiver operating characteristic(ROC)curve.Results The serum levels of t-PSA,f-PSA,and chromogranin A in the prostate cancer group were higher than those in the prostate benign tumors group and those in the healthy control group(all P<0.05).The accuracy,sensitivity,specificity of the combination of the 3 indicators for prostate cancer and benign prostate diseases were 92.9%,94.3%,and 92.1%.The serum levels of f-PSA,t-PSA,and CgA decreased rapidly after prostate cancer resection.Conclusions The combination of t-PSA,f-PSA,and chromogranin A is the optimal combination pattern of tumor markers,which is helpful for the diagnosis of prostate cancer and postoperative observation.

关 键 词:前列腺癌 前列腺特异性抗原 嗜铬粒蛋白A 

分 类 号:R737.25[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象